ATLN SIX Swiss Exchange
|At 17:31:57 CET 22/02/2017|
We strive to treat more patients with ground-breaking therapies. This mission inspires and motivates us.
Actelion’s strategy is designed to create value by leveraging the Company’s many strengths. These include its global leadership in the field of pulmonary arterial hypertension (PAH) therapy, a strong and effective worldwide specialty commercial organization, a highly productive discovery capability and a unique company culture that focuses on delivering innovative medicines that improve patient’s lives.
We are the leaders in PAH therapy and, with our PAH products, we will continue to lead well into the future. During this time we must build our portfolio – through R&D and/or business development, to find additional meaningfully differentiated products to benefit patients. To realize our potential, we need to have a solid business – which means never losing sight of spending, whilst maintaining quality in all that we do.
Pursue top quality science, internally and externally,
balanced with medical need
and commercial potential.
Develop projects ourselves and
seek partners or out-licence when necessary to maximize value.
Expand innovative commercial capabilities to new customers and regions. Manage alliances, putting the product first.
Quality is crucial and needs to be ingrained across all functions.